Nigeria Gets Game-Changing HIV Prevention Shot in 2026

Imagine preventing HIV with just two shots a year instead of taking a pill every single day. That's about to become reality for millions of Nigerians.

Nigeria is set to introduce lenacapavir in March 2026, a revolutionary twice-yearly injectable that prevents HIV infection with 99.9% effectiveness. The National Agency for the Control of AIDS has already secured regulatory approval and completed readiness assessments in 10 states, including Lagos, Kano, Akwa Ibom, and Anambra.

The drug works by targeting HIV's protective shell, stopping the virus from replicating before it can establish infection. Unlike daily oral prevention pills that require strict adherence, lenacapavir reduces the medication burden to just two doses per year.

What makes this truly groundbreaking is the price. Initially listed at $28,000 per person annually in wealthy countries, Nigeria joined other nations last September in negotiating a massive price reduction to about $40 per year for low and middle-income countries.

The World Health Organization formally recommended the injectable last July as countries recorded 1.3 million new HIV infections globally in 2024. With 1.9 million Nigerians living with HIV and prevalence at 1.3% among people aged 15 to 49, the country has made progress expanding treatment but prevention gaps remain.

Daily prevention pills have been available for years, but uptake has been limited by stigma, pill fatigue, and access barriers. A discreet injection every six months could change everything for populations most at risk, including adolescent girls, young women, sex workers, and men who have sex with men.

The Ripple Effect

South Africa, Eswatini, and Zambia have already begun rolling out the injection, marking the first public use in Africa. Nigeria's preparations include training healthcare workers across implementation states and developing awareness materials to build demand before distribution begins.

Healthcare workers in 10 states have completed specialized training to administer the drug and support patients. The National Agency for the Control of AIDS is working to ensure the injection reaches communities where it can have the greatest impact.

This isn't just about one new drug. It represents a shift toward more sustainable, patient-friendly HIV prevention that works with people's lives instead of demanding perfect daily compliance.

With funding uncertainties facing global HIV programs, Nigeria's ability to offer such effective prevention at an affordable price could help the country build a more self-reliant response to the epidemic. More than 630,000 people died from HIV-related causes globally in 2024, with 65% of people living with HIV residing in Africa.

The countdown to March 2026 has begun, and with it comes renewed hope that Nigeria can dramatically reduce new infections and move closer to ending AIDS as a public health threat.